English
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)

Only registered users can translate articles
Log In/Sign up
The link is saved to the clipboard
StatusNot yet recruiting
Sponsors
University of Colorado Denver School of Medicine Barbara Davis Center

Keywords

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage kidney disease (ESKD). The disorder is characterized by development and continued growth of multiple cysts requiring renal replacement therapy in 50% of patients by age 60 years. However, ADPKD is also a complex metabolic disorder defined by insulin resistance (IR) and mitochondrial dysfunction which may be causally related to cyst expansion, kidney function decline and contribute to reduced life expectancy. Renal hypoxia, stemming from a potential metabolic mismatch between increased renal energy expenditure and impaired substrate utilization, is proposed as a novel unifying early pathway in the development and expansion of renal cysts in ADPKD. By examining the interplay between renal O2 consumption and energy utilization in young adults with and without ADPKD, the investigators hope to identify novel therapeutic targets to impede development of cyst expansion in future trials.
The investigators propose to address the specific aims in a cross-sectional study with 20 adults with ADPKD (50% female, ages 18-40 years). Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance). For this protocol, participants will complete a one day study visit at Children's Hospital Colorado. Patients will undergo a dual energy x-ray absorptiometry (DXA) to assess body composition, and a 11C-acetate positron emission tomography (PET/CT) scan to quantify renal O2 consumption. After the PET/CT, participants will undergo a hyperinsulinemic-euglycemic clamp while fasting to quantify insulin sensitivity. Glomerular Filtration Rate (GFR) and Effective Renal Plasma Flow (ERPF) will be measured by iohexol and PAH clearances during the hyperinsulinemic-euglycemic clamp.

Dates

Last Verified: 04/30/2020
First Submitted: 05/18/2020
Estimated Enrollment Submitted: 05/26/2020
First Posted: 05/28/2020
Last Update Submitted: 05/26/2020
Last Update Posted: 05/28/2020
Actual Study Start Date: 06/30/2020
Estimated Primary Completion Date: 06/29/2022
Estimated Study Completion Date: 12/30/2022

Condition or disease

Polycystic Kidney Disease, Adult
Polycystic Kidney, Autosomal Dominant

Intervention/treatment

Drug: Adults with autosomal dominant polycystic kidney disease

Drug: Adults with autosomal dominant polycystic kidney disease

Radiation: Adults with autosomal dominant polycystic kidney disease

Phase

-

Arm Groups

ArmIntervention/treatment
Adults with autosomal dominant polycystic kidney disease
All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
Drug: Adults with autosomal dominant polycystic kidney disease
Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Healthy Controls
Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance).

Eligibility Criteria

Ages Eligible for Study 18 Years To 18 Years
Sexes Eligible for StudyAll
Sampling methodProbability Sample
Accepts Healthy VolunteersYes
Criteria

Inclusion Criteria:

- Patients with Autosomal dominant polycystic kidney disease

- Age 18-40 years

- BMI >= 18.5 and <30 kg/m2

- Weight <350 lbs

Exclusion Criteria:

- Diabetes mellitus, based on previous diagnosis

- Albuminuria (≥30mg/g) or estimated glomerular filtration rate (eGFR) <75ml/min/1.73m2

- Pregnancy or nursing

- Anemia

- Allergy to shellfish or iodine

- Vaptan therapy (e.g. tolvaptan)

- Uncontrolled hypertension (average ≥140/90 mmHg)

Outcome

Primary Outcome Measures

1. Renal oxygen consumption [30 minutes]

11-C Acetate PET/CT

2. Insulin Sensitivity [4.5 hours]

Hyperinsulinemic-Euglycemic Clamp

Secondary Outcome Measures

1. Mitochondrial Function [5 minutes]

Blood draw for mitochondrial DNA copy number

2. Mitochondrial Function [5 minutes]

Blood draw for untargeted metabolite assessment of the tricyclic acid (TCA) cycle

3. Mitochondrial Function [5 minutes]

Blood draw for targeted assessment and quantification of glucose oxidation using an established metabolite panel

4. Mitochondrial Function [5 minutes]

Blood draw for untargeted metabolite assessment of Free Fatty Acid (FFA) oxidation

5. Glomerular Filtration Rate (GFR) [3 hours]

Iohexol Clearance Study

6. Effective Renal Plasma Flow (ERPF) [2.5 hours]

PAH Clearance Study

7. Renin-Angiotensin-Aldosterone-System Activity [5 minutes]

Blood draw for Plasma Renin levels

8. Renin-Angiotensin-Aldosterone-System Activity [5 minutes]

Blood draw for Angiotensin II levels

9. Renin-Angiotensin-Aldosterone-System Activity [5 minutes]

Blood draw for Copeptin levels

10. Kidney Injury Biomarkers [5 minutes]

Chitinase-3-like protein 1 (YKL-40) levels

11. Kidney Injury Biomarkers [5 minutes]

Blood draw for Neutrophil gelatinase-associated lipocalin (NGAL) levels

12. Kidney Injury Biomarkers [5 minutes]

Blood draw for Kidney Injury Molecule 1 (KIM-1) levels

13. Kidney Injury Biomarkers [5 minutes]

Blood draw for Interleukin-18 (IL-18) levels

14. Kidney Injury Biomarkers [5 minutes]

Blood draw for Tumor Necrosis Factor Receptor 1/2 (TNF-R 1/2) levels

15. Kidney Injury Biomarkers [5 minutes]

Blood draw for monocyte chemoattractant protein-1 (MCP-1) levels

Join our facebook page

The most complete medicinal herbs database backed by science

  • Works in 55 languages
  • Herbal cures backed by science
  • Herbs recognition by image
  • Interactive GPS map - tag herbs on location (coming soon)
  • Read scientific publications related to your search
  • Search medicinal herbs by their effects
  • Organize your interests and stay up do date with the news research, clinical trials and patents

Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research

Google Play badgeApp Store badge